Protagonist Therapeutics Inc (PTGX)
41.04
-1.63
(-3.82%)
USD |
NASDAQ |
Nov 14, 16:00
41.04
0.00 (0.00%)
After-Hours: 20:00
Protagonist Therapeutics Cash from Operations (Quarterly): -27.86M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -27.86M |
| June 30, 2024 | 268.62M |
| March 31, 2024 | -27.43M |
| December 31, 2023 | 16.96M |
| September 30, 2023 | -26.61M |
| June 30, 2023 | -26.24M |
| March 31, 2023 | -34.35M |
| December 31, 2022 | -31.64M |
| September 30, 2022 | -25.20M |
| June 30, 2022 | -13.64M |
| March 31, 2022 | -37.67M |
| December 31, 2021 | -26.94M |
| September 30, 2021 | -28.47M |
| June 30, 2021 | -23.70M |
| March 31, 2021 | -28.76M |
| December 31, 2020 | -18.87M |
| September 30, 2020 | -16.29M |
| June 30, 2020 | -21.48M |
| March 31, 2020 | -15.85M |
| December 31, 2019 | -14.29M |
| Date | Value |
|---|---|
| September 30, 2019 | -14.25M |
| June 30, 2019 | 3.67M |
| March 31, 2019 | -16.66M |
| December 31, 2018 | -10.14M |
| September 30, 2018 | -9.276M |
| June 30, 2018 | -15.40M |
| March 31, 2018 | -15.14M |
| December 31, 2017 | -14.15M |
| September 30, 2017 | 40.70M |
| June 30, 2017 | -12.33M |
| March 31, 2017 | -10.36M |
| December 31, 2016 | -9.68M |
| September 30, 2016 | -6.98M |
| June 30, 2016 | -8.073M |
| March 31, 2016 | -5.239M |
| December 31, 2015 | -4.739M |
| September 30, 2015 | -3.769M |
| June 30, 2015 | -3.444M |
| March 31, 2015 | -2.433M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-37.67M
Minimum
Mar 2022
268.62M
Maximum
Jun 2024
-7.984M
Average
-25.72M
Median
Cash from Operations (Quarterly) Benchmarks
| Johnson & Johnson | 7.993B |
| Assembly Biosciences Inc | -17.10M |
| Precision BioSciences Inc | -5.912M |
| Entrada Therapeutics Inc | -24.27M |
| NovaBay Pharmaceuticals Inc | -2.061M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -208.71M |
| Cash from Financing (Quarterly) | 12.05M |
| Free Cash Flow | 229.23M |
| Free Cash Flow Per Share (Quarterly) | -0.4636 |
| Free Cash Flow to Equity (Quarterly) | -28.64M |
| Free Cash Flow to Firm (Quarterly) | -28.64M |
| Free Cash Flow Yield | 9.04% |